Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Wacker Neuson FY11 Profit Rises - Quick Facts

Wacker Neuson SE (WKRCF.PK) posted fiscal 2011 consolidated earnings of 85.8 million euros or 1.22 euros per share versus 23.9 million euros or 0.34 euros per share last year.

EBITDA for the year rose to 162.6 million euros from 77.8 million euros in the prior year.

Revenue improved year-over-year to 991.6 million euros from 757.9 million euros.

Looking forward, assuming market trends remain positive, the Executive Board predicts overall revenue for fiscal 2012 of around 1.1 billion euros and an EBITDA margin of at least 15 percent. It also expects double-digit revenue growth in 2013, with the same high levels of profitability

Click here to receive FREE breaking news email alerts for Wacker Neuson SE and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Fashion retailer Gap Inc. said Thursday after the markets closed that its second quarter profit rose 10% from last year, helped by higher sales and a gain from asset sale. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarter sales. Separately, Gap announced plans to enter India through franchise-operated Gap brand stores in 2015. While buying interest was somewhat subdued, stocks moved mostly higher over the course of the trading day on Thursday. The gains on the day extended the recent upward trend by the markets, lifting the S&P 500 to a new record closing high. Republicans have not found much to like about President Barack Obama's nearly six years in office, but the results of a new Washington Post-ABC News poll show that a vast majority support the president's decision to launch airstrikes in Iraq.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.